Valneva SE
OTC: INRLF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Thomas Lingelbach
- Employees
- 713
- Headquarters
- Saint-Herblain, France
- IPO year
- 2010
- Market cap
- $474.1M
- Website
- https://valneva.com
Loading INRLF…
Loading profile data…Frequently asked questions about INRLF
What does Valneva SE (INRLF) do?
Valneva SE operates as a specialized biopharmaceutical entity, primarily focused on the creation and commercialization of preventative vaccines for infectious diseases where effective treatments are currently lacking. Its existing range of vaccines for international travelers includes IXIARO, an inactivated, Vero cell culture-based immunization...
Where does INRLF trade?
Valneva SE (INRLF) trades on the Other OTC.
What sector is INRLF in?
Valneva SE (INRLF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Valneva SE?
Thomas Lingelbach is the chief executive officer of Valneva SE (INRLF).
Where is Valneva SE headquartered?
Valneva SE is headquartered in France.
Does INRLF pay a dividend?
Valneva SE (INRLF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did INRLF go public?
Valneva SE (INRLF) completed its initial public offering in 2010.